By clicking “Accept,” you agree to the use of cookies and similar technologies on your device as set forth in our Cookie Policy and our Privacy Policy. Please note that certain cookies are essential for this website to function properly and do not require user consent to be deployed.

Brain Reboot

New Treatments for Healing Depression

Contributors

By Michael Henry, MD

Formats and Prices

Price

$14.99

Price

$19.99 CAD

HEAL YOUR DEPRESSION AND REGAIN YOUR LIFE—WITH THREE NEW TOOLS ON THE CUTTING EDGE OF TREATMENT
 
Everyone feels depressed sometimes. But a sustained lack of energy, a pro-found inability to enjoy life, or an overwhelming sadness that can render unbearable pain may be symptoms of something more. If you suffer from any of these symptoms, you may be one of 300 million people worldwide who have depression. While we often think of pharmaceutical treatments as the best way to treat depression, the truth is that for many people they either don’t work or lose their efficacy after a time. But there is hope in the form of three groundbreaking therapies: ketamine, transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT). In Brain Reboot, you’ll learn:
  • How to get an accurate diagnosis
  • How to determine what treatment(s) are best for you
  • The efficacy of ketamine, TMS, and ECT
  • A clear summary of benefits and potential side effects
  • Step-by-step information for each treatment and FAQs
  • Tips for supplementing your recovery with exercise, nutrition, and sleep
  • Treatments on the horizon

Dr. Michael Henry’s life mission is to help anyone suffering with treatment-resistant depression; in Brain Reboot he provides everything you need to know about using ketamine, TMS, and ECT to regain your self and your life.

On Sale
Nov 29, 2022
Page Count
304 pages
Publisher
Balance
ISBN-13
9780306925184

Michael Henry, MD

About the Author

Dr. Michael Henry is the director of Electroconvulsive Therapy and medical director of Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital and an Associate Professor in Psychiatry at Harvard Medical School. He completed his residency in psychiatry at the University of Massachusetts Medical Center in Worcester, MA, and a fellowship in clinical pharmacology at the National Institute of Mental Health in Bethesda, MD. He is a member of the American Society of Clinical Psychopharmacology, and the International Society for ECT and Neurostimulation, and is a Fellow of the International College of Neuropsychopharmacology. He has presented his work treating patients with these three treatments both nationally and internationally. 
 

Learn more about this author